| 1 |
NCT02047695 |
Completed |
Women With Migraine With Aura Neuroimaging Study |
|
|
Observational
|
|
- Odense University Hospital
- Glostrup University Hospital, Copenhagen
- Copenhagen University Hospital, Hvidovre
- University of Southern Denmark
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Evidence of white matter hyperintensities or subclinical ischaemic stroke confirmed by MRI
- Evidence of other structural and functional changes in brain
|
345 |
Female |
30 Years to 60 Years (Adult) |
NCT02047695 |
S-20100126 |
WOMAN |
February 2011 |
April 2015 |
April 2017 |
January 28, 2014 |
April 4, 2017 |
|
|
|
| 2 |
NCT03472417 |
Completed |
Partial Rebreathing in the Treatment of Migraine With Aura |
|
- Device: Active partial rebreathing device
- Device: Dummy partial rebreathing device
|
Interventional
|
Not Applicable |
- University of Aarhus
- Aarhus University Hospital
- BalancAir
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Headache Intensity Difference at 0 vs 2 hours post-treatment
- Headache Intensity Difference at 0 and 1 hour post-treatment (0-3 point scale)
- Pain reduction/relief at 1 hour
- (and 13 more...)
|
18 |
All |
18 Years to 60 Years (Adult) |
NCT03472417 |
2016-003683-39 |
CapnoMigra |
November 2016 |
September 2017 |
September 2017 |
March 21, 2018 |
March 23, 2018 |
|
- Pain and Headache Clinic, Aarhus University Hospital
Aarhus, Denmark
|
|
| 3 |
NCT02708797 |
Completed |
Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura. |
|
- Other: Magnetic resonance imaging
- Other: Transcranial Doppler
|
Interventional
|
Not Applicable |
- University Hospital, Toulouse
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Correlation between the density of the pontine grey matter evaluated with resonance magnetic imaging, and cerebral autoregulation measured with Transcranial Doppler in migraine with aura patients and controls.
- Comparison of brainstem grey matter density between migraine with aura patients and controls with magnetic resonance imaging
- Comparison of cerebral autoregulation between migraine with aura patients and controls with Transcranial Doppler
- (and 6 more...)
|
46 |
All |
30 Years to 55 Years (Adult) |
NCT02708797 |
RC31/15/7815
2015-A01982-47 |
MINOTAURE |
May 2016 |
April 2017 |
April 2017 |
March 15, 2016 |
February 6, 2018 |
|
- CHU Toulouse
Toulouse, France
|
|
| 4 |
NCT00893594 |
Unknown † |
Efficacy of Sumatriptan With Naprosyn in Migraine With Aura |
|
- Drug: sumatriptan with naprosyn
- Drug: placebo
|
Interventional
|
Not Applicable |
- Dent Neurologic Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Primary outcome measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn).
- Secondary outcomes will be percentage of patients with pain relief at 2 and 4 hours.
|
30 |
All |
18 Years to 50 Years (Adult) |
NCT00893594 |
113010 |
|
October 2010 |
December 2015 |
December 2015 |
May 6, 2009 |
February 19, 2015 |
|
- Dent Neurologic Institute
Amherst, New York, United States
|
|
| 5 |
NCT01388894 |
Unknown † |
Functional MRI and MRA in Migraine With Aura |
|
|
Observational
|
|
- Glostrup University Hospital, Copenhagen
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
|
80 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01388894 |
MA-01 |
|
December 2010 |
|
|
July 7, 2011 |
July 7, 2011 |
|
- Danish Headache Center
Glostrup, Denmark
|
|
| 6 |
NCT00332007 |
Completed |
Tonabersat in the Prophylaxis of Migraine With Aura |
|
- Drug: Tonabersat
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Minster Research Ltd
- University of Copenhagen
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Difference in the mean number of aura attacks experienced between treatment groups
- Difference in the mean number of migraine headache days between treatment groups
- Incidence of adverse events
- (and 9 more...)
|
39 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00332007 |
TON/02/05-CLIN |
|
May 2006 |
August 2008 |
August 2008 |
May 31, 2006 |
August 31, 2009 |
|
- Danish Headache Centre, Department of Neurology, Glostrup Hospital
Copenhagen, Denmark
|
|
| 7 |
NCT00126035 |
Completed |
Study With Migraid Device in Acute, Early Treatment of Migraine With Typical Aura |
- Migraine With Typical Aura
|
|
Interventional
|
Not Applicable |
- Profess Medical Consultancy
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of attacks that were "pain free" at t = 120 minutes without using rescue medication
- Percentage of responders
- Percentage of attacks that were “pain free” at t = 30 minutes, t = 60 minutes, t = 90 minutes, t =150 minutes, t =180 minutes and t = 24 hours without using rescue medication
- (and 7 more...)
|
134 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00126035 |
03-MIG-01 |
|
February 2004 |
|
December 2004 |
August 2, 2005 |
August 17, 2005 |
|
- Multicentre study with 21 General practitioners
Haarlem, Noord Holland, Netherlands
|
|
| 8 |
NCT03185143 |
Completed |
Oral ALLOD-2 vs. Oral Sumatriptan and vs. Placebo in the Acute Treatment of Migraine With Associated Nausea (ANODYNE-2) |
- Migraine With and Without Aura
|
- Drug: ALLOD-2 Capsules
- Drug: Sumatriptan 100 mg Capsules
- Drug: Placebo capsules
|
Interventional
|
Phase 2
Phase 3 |
- Allodynic Therapeutics, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The proportion of patients having no headache pain at 2 hours.
- The proportion of patients having the absence of the most bothersome migraine-associated symptom at 2 hours.
- The proportion of patients having the absence of nausea, photophobia, phonophobia, and neck/shoulder pain at 2 hours.
- (and 4 more...)
|
36 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03185143 |
ANODYNE-2 |
|
June 27, 2017 |
May 7, 2018 |
May 7, 2018 |
June 14, 2017 |
May 11, 2018 |
|
- Annette C. Toledano, M.D.
North Miami, Florida, United States
|
|
| 9 |
NCT03338920 |
Recruiting |
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents |
- Acute Migraine With or Without Aura
|
- Drug: sumatriptan nasal powder
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants who were headache pain free at 120 minutes after treatment
- Number of participants with headache relief at 120 minutes after treatment
- Number of participants who were headache pain free any time after treatment
- (and 9 more...)
|
420 |
All |
12 Years to 17 Years (Child) |
NCT03338920 |
17-AVP-825-301 |
|
November 2, 2017 |
November 2019 |
November 2019 |
November 9, 2017 |
May 24, 2018 |
|
- Phoenix Children's Hospital
Phoenix, Arizona, United States - Fullerton Neurology and Headache Center
Fullerton, California, United States - Alpine Clinical Research Center, Inc.
Boulder, Colorado, United States - (and 20 more...)
|
|
| 10 |
NCT00449540 |
Completed
Has Results |
Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura |
|
- Device: Active Transcranial Magnetic Stimulation (TMS) Device
- Device: Sham TMS Device
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Percentage of Participants Experiencing no Pain at Two Hours Post-treatment
- Percentage of Participants Who Have Symptoms of Nausea
- Percentage of Participants Who Have Symptoms Phonophobia
- Percentage of Participants Who Have Photophobia
|
201 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00449540 |
NL-2006-001 |
|
August 2006 |
January 2008 |
March 2008 |
March 20, 2007 |
August 15, 2011 |
August 10, 2011 |
- San Francisco Headache Clinic
San Francisco, California, United States - Mile High Research Center
Denver, Colorado, United States - Diamond Headache Clinic, LTD
Chicago, Illinois, United States - (and 11 more...)
|
|
| 11 |
NCT00920686 |
Completed
Has Results |
Study of NXN 188 for the Treatment of Migraine With Aura |
|
- Drug: NXN-188
- Drug: placebo
- Drug: sumatriptan succinate
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time (Hours) to First Use of Rescue Medication
- Headache Relief and Recurrence (Observed Cases)
- 2 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea
- (and 2 more...)
|
239 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00920686 |
NXN-188-203 |
|
June 2009 |
March 2010 |
March 2010 |
June 15, 2009 |
August 11, 2014 |
August 11, 2014 |
- C. Philip O'Carrroll, MD, Inc.
Newport Beach, California, United States - The Research Center of Southern California, LLC
Oceanside, California, United States - San Francisco Headache Clinic
San Francisco, California, United States - (and 13 more...)
|
|
| 12 |
NCT00687947 |
Completed |
Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA) |
- Familial Hemiplegic Migraine
- Migraine With Aura
- Healthy
|
|
Interventional
|
Not Applicable |
- Danish Headache Center
- EUROHEAD
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Migraine and associated symptoms
- Migraine aura
|
30 |
All |
Child, Adult, Older Adult |
NCT00687947 |
FHM-CGRP-MA-2008 |
CGRP-2008 |
May 2008 |
August 2008 |
August 2008 |
June 2, 2008 |
August 3, 2009 |
|
- Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital
Glostrup, Copenhagen, Denmark
|
|
| 13 |
NCT03472378 |
Recruiting |
Can DFN-15 Terminate Migraine With Allodynia? |
- Migraine With Aura
- Migraine Without Aura
- Allodynia
|
- Drug: DFN-15
- Other: Placebo
|
Interventional
|
Phase 2 |
- Hartford Hospital
- Rami Burstein, PhD, Beth Israel Deaconess Medical Center
- Dr. Reddy's Laboratories Limited
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Headache Pain Intensity
- Allodynia
|
100 |
All |
18 Years to 64 Years (Adult) |
NCT03472378 |
HHC-2017-0224 |
|
April 1, 2018 |
August 1, 2018 |
September 1, 2018 |
March 21, 2018 |
March 23, 2018 |
|
- Hartford HealthCare Headache Center
West Hartford, Connecticut, United States
|
|
| 14 |
NCT01388699 |
Unknown † |
Migraine and Endothelial Dysfunction |
|
|
Observational
|
|
- Charite University, Berlin, Germany
|
Other |
- Observational Model: Case Control
|
- Endothelial Microparticles
- Levels of circulating Endothelial Progenitor Cells
- Digital pulse volume change
|
60 |
Female |
18 Years to 50 Years (Adult) |
NCT01388699 |
FF_NCRC_Migraine&ED |
|
October 2010 |
August 2011 |
September 2011 |
July 7, 2011 |
July 7, 2011 |
|
- Center for Stroke Research Berlin
Berlin, Germany
|
|
| 15 |
NCT02253004 |
Completed |
Induction of Migraine Aura With Cilostazol |
|
- Drug: Cilostazol
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Aura
- Migraine
- Endothelial response
|
16 |
All |
18 Years to 50 Years (Adult) |
NCT02253004 |
H-3-2013-166
2013-004188-29 |
|
September 2014 |
August 2015 |
August 2015 |
October 1, 2014 |
August 21, 2015 |
|
- Herlev Hospital, Dept Neurology
Herlev, Denmark
|
|
| 16 |
NCT01004263 |
Completed
Has Results |
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3) |
- Acute Migraine With or Without Aura in Adolescents
|
- Drug: rizatriptan benzoate
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose
- Number of Participants With AEs Within 14 Days Post Any Dose
- Number of Participants Discontinued From Study Due to AEs Occurring Within 24 Hours Post Dose
- (and 2 more...)
|
674 |
All |
12 Years to 17 Years (Child) |
NCT01004263 |
0462-086
2009_680 |
|
December 1, 2009 |
April 18, 2011 |
April 18, 2011 |
October 29, 2009 |
June 19, 2017 |
May 4, 2012 |
|
|
| 17 |
NCT02906085 |
Not yet recruiting |
Endothelin-1 as a Potential Trigger of Migraine Aura |
|
- Drug: Endothelin-1
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Glostrup University Hospital, Copenhagen
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Occurrence of migraine aura
- Cerebral vasoconstriction: transcranial doppler
- Cerebral vasoconstriction: MR angiography
- (and 2 more...)
|
24 |
All |
18 Years to 40 Years (Adult) |
NCT02906085 |
H-16022143 |
|
October 2016 |
October 2017 |
|
September 19, 2016 |
September 19, 2016 |
|
- Danish Headache Center
Glostrup, Denmark
|
|
| 18 |
NCT02795351 |
Recruiting |
Induction of Migraine Aura With Sildenafil |
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Aura and migraine like headache
- Markers of endothelial function in blood
- Migraine without aura
|
16 |
All |
18 Years to 50 Years (Adult) |
NCT02795351 |
H-15008491 |
|
June 2015 |
June 2018 |
August 2018 |
June 10, 2016 |
March 22, 2018 |
|
- Department of Neurology, Herlev-Gentofte Hospital
Herlev, Denmark
|
|
| 19 |
NCT00877838 |
Unknown † |
Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura |
|
- Drug: NXN-188
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Danish Headache Center
- NeurAxon Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- The severity of headache measured with a 4 point scale (The Headache Severity Score (HSS))
- Absence of headache
- The occurence of any type(s) of adverse events(s)
- (and 2 more...)
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00877838 |
NXN-188-202 |
|
May 2009 |
March 2010 |
December 2010 |
April 8, 2009 |
July 28, 2009 |
|
- Danish Headache Center
Glostrup, Denmark
|
|
| 20 |
NCT03143465 |
Recruiting |
Pharmacologically Triggered Migraine Without Aura and Neuroimaging |
|
- Drug: Calcitonin Gene-Related Peptide
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- CGRP and sildenafil induced MRI-changes
|
36 |
All |
18 Years to 50 Years (Adult) |
NCT03143465 |
H-15019063 |
|
August 2016 |
December 2018 |
December 2018 |
May 8, 2017 |
May 8, 2017 |
|
- Danish Headache Center, University Hospital
Glostrup, Denmark
|
|
| 21 |
NCT01319825 |
Unknown † |
Preventive Treatment of Episodic and Chronic Migraine |
- Migraine With Aura
- Migraine Without Aura
- Chronic Migraine
|
|
Interventional
|
Phase 4 |
- California Medical Clinic for Headache
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduction in number of all headache days per month in the last month of stable dosing, compared to baseline
- Reduction in number of migraine days per month in the last month of stable dosing compared to baseline.
- Improvement in headache index score
- (and 4 more...)
|
45 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01319825 |
SAV-MD-26 |
|
April 2011 |
May 2012 |
July 2012 |
March 22, 2011 |
March 22, 2011 |
|
- California Medical Clinic for Headache
Santa Monica, California, United States
|
|
| 22 |
NCT03061734 |
Completed |
Oral ALLOD-2 vs. Its Components & vs. Placebo in the Acute Treatment of Migraine (ANODYNE-1) |
- Migraine With or Without Aura
|
- Drug: ALLOD-2
- Drug: ALLOD-2H
- Drug: Component A (regular dose)
- (and 2 more...)
|
Interventional
|
Phase 2
Phase 3 |
- Allodynic Therapeutics, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The proportion of patients having no headache pain for ALLOD-2 vs. placebo at 2 hours.
- The proportion of patients having absence of most bothersome migraine-associated symptom-for ALLOD-2 vs. placebo at 2 hours.
- The proportion of patients having absence of nausea, photophobia, phonophobia, and neck/shoulder pain for ALLOD-2 and ALLOD-2H vs. placebo at 2 hours.
- (and 4 more...)
|
92 |
All |
18 Years and older (Adult, Older Adult) |
NCT03061734 |
ANODYNE-1 |
|
February 18, 2017 |
February 8, 2018 |
February 8, 2018 |
February 23, 2017 |
March 20, 2018 |
|
- Annette C. Toledano MD
North Miami, Florida, United States
|
|
| 23 |
NCT00505570 |
Terminated |
PRIMA PFO Migraine Trial |
- Migraine
- Migraine With Aura
- Patent Foramen Ovale
- PFO
|
- Device: AMPLATZER® PFO Occluder Device
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Migraine headache frequency
- Responder rate; Acute migraine medication use; Quality of life evaluations; Effects of Anti-thrombotic medications; Adverse events; PFO Closure
|
107 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00505570 |
AGA010E |
PRIMA |
May 2006 |
February 2013 |
February 2013 |
July 23, 2007 |
April 8, 2015 |
|
- University of Calgary- Foothills Hospital
Calgary, Alberta, Canada - Alberta Health Services and the University of Alberta
Edmonton, Alberta, Canada - University of British Columbia
Vancouver, British Columbia, Canada - (and 14 more...)
|
|
| 24 |
NCT01896167 |
Completed |
Migraine With Aura Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow by Hypoxia |
|
- Other: Hypoxia
- Other: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Headache and aura
- artery circumference
- Cerebral blood flow
- (and 2 more...)
|
34 |
All |
18 Years to 50 Years (Adult) |
NCT01896167 |
H-4-2012-182 |
|
April 2013 |
September 2014 |
September 2014 |
July 11, 2013 |
February 12, 2015 |
|
- Nanna Arngrim
Glostrup, Denmark
|
|
| 25 |
NCT01402479 |
Completed |
An Open-labeled Trial of Ramipril in Patients With Migraine |
- Migraine With Hypertension
|
|
Interventional
|
Phase 2 |
- Seoul National University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
50 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT01402479 |
0408-131-005 |
|
October 2004 |
July 2005 |
July 2005 |
July 26, 2011 |
August 8, 2011 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
|
| 26 |
NCT01257880 |
Completed
Has Results |
Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP) |
- Migraine With Aura
- Patent Foramen Ovale
|
|
Observational
|
|
- Swedish Medical Center
- University of Washington
- Coherex Medical
- (and 2 more...)
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Embolic Tracks
- Cerebral Vasomotor Reactivity (VMR)
- Platelet Activation
- (and 4 more...)
|
31 |
All |
18 Years to 55 Years (Adult) |
NCT01257880 |
4865S-09 |
CAMP |
January 2010 |
May 2011 |
May 2011 |
December 10, 2010 |
September 27, 2011 |
September 21, 2011 |
- Swedish Medical Center
Seattle, Washington, United States - The University of Washington
Seattle, Washington, United States
|
|
| 27 |
NCT03361423 |
Recruiting |
Evaluation of a Novel Device for Treatment of Migraine Headache |
- Migraine Without Aura
- Migraine With Aura
|
- Device: Nerivio Migra-1 active device
- Device: Nerivio Migra-1 Sham device
|
Interventional
|
Not Applicable |
- Theranica
- Rambam Health Care Campus
- Northwell Health
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of reduction of migraine headache post 2 hours from treatment
- Percentage of reduction of most bothersome migraine-associated symptom (MBS) relief post 2 hours treatment
- Percentage of reduced Migraine Headache AND MBS Relief post 2 hours post tresatment
- Percentage of pain disappearance 2 hours post treatment
|
270 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03361423 |
TCH003 |
|
December 17, 2017 |
June 30, 2018 |
August 30, 2018 |
December 4, 2017 |
February 19, 2018 |
|
- Hartford Headache Center
Hartford, Connecticut, United States - Mercy Hospital
Saint Louis, Missouri, United States - Northwell Health, Inc
New York, New York, United States - (and 4 more...)
|
|
| 28 |
NCT01814189 |
Completed |
Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment |
- Migraine With Aura
- Migraine Without Aura
|
- Drug: Sumatriptan+Promethazine (SPr)
|
Interventional
|
Phase 3 |
- Shahid Beheshti University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Complete headache relief
- Headache improvement.
- Using the second dose of study medications.
- (and 3 more...)
|
350 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01814189 |
SB-045 |
|
January 2013 |
April 2013 |
April 2013 |
March 19, 2013 |
July 30, 2013 |
|
- Department of Neurology, Emam Hossein Hospital
Tehran, Iran, Islamic Republic of
|
|
| 29 |
NCT01741714 |
Completed |
Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine |
- Migraine With Aura
- Migraine Without Aura
|
- Other: Sham chiropractic manipulative therapy
- Other: Chiropractic spinal manipulative therapy
|
Interventional
|
Phase 3 |
- University Hospital, Akershus
- Norwegian Foundation for Health and Rehabilitation
- Norwegian Chiropractic Association
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number og headache days
- Headache duration
- Self reported VAS
- (and 2 more...)
|
104 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01741714 |
Migraine-K34KSF-AHUS
2829002 |
|
February 2013 |
March 2015 |
September 2015 |
December 5, 2012 |
December 31, 2015 |
|
- Research Centre, Akershus University Hospital
Lørenskog, Norway
|
|
| 30 |
NCT03194555 |
Active, not recruiting |
Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in Episodic Migraine Prevention (ANODYNE-3) |
- Migraine With or Without Aura
|
- Drug: ALLOD-2 Capsules
- Drug: Placebo Capsules
|
Interventional
|
Phase 2
Phase 3 |
- Allodynic Therapeutics, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in the mean number of migraine/probable migraine headache days.
- Change from baseline in the mean number of headache days.
- Proportion of patients with 50% or more reduction in migraine/probable migraine headache days.
- (and 9 more...)
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT03194555 |
ANODYNE-3 |
|
August 1, 2017 |
August 2018 |
October 2018 |
June 21, 2017 |
April 17, 2018 |
|
- Annette Toledano, M.D.
North Miami, Florida, United States
|
|
| 31 |
NCT01859481 |
Completed |
Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study |
- Migraine Without Aura
- Migraine With Aura
|
- Drug: Placebo
- Drug: Eletriptan HBr 40 mg
- Drug: Eletriptan HBr 80 mg
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Consistency of headache response (3 responses out of 3 active treated attacks) . Headache response was defined as migraine headache pain of moderate or severe intensity pre dose becoming basent or mild within 2 hours post dose.
- Consistency of headache response (2 responses out of 3 active treated attacks). Headache response was defined as migraine headache pain of moderate or severe intensity pre dose becoming basent or mild within 2 hours post dose.
|
971 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01859481 |
A1601015 |
|
March 2000 |
March 2002 |
March 2002 |
May 22, 2013 |
May 22, 2013 |
|
- Eeuwfeestkliniek
Antwerpen, Belgium - A.Z. Sint Jan
Brugge, Belgium - Cliniques Universitaires St Luc
Bruxelles, Belgium - (and 145 more...)
|
|
| 32 |
NCT01989936 |
Completed |
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan |
- Migraine With or Without Aura
|
- Drug: Placebo
- Drug: Eletriptan 40 mg
- Drug: Eletriptan 80 mg
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The primary efficacy endpoint was 2-h headache response after taking the first dose of study medication for the first attack
- Sustained response was defined as achieving a headache response within 2 h post dose, with no recurrence or rescue medication needed
|
446 |
All |
18 Years to 68 Years (Adult, Older Adult) |
NCT01989936 |
A1601006 |
|
January 1999 |
September 2000 |
September 2000 |
November 21, 2013 |
November 21, 2013 |
|
- Arhus Kommunehospital
Arhus C, Denmark - Centralsygehuset I Esbjerg
Esbjerg, Denmark - Kas Glostrup
Glostrup, Denmark - (and 40 more...)
|
|
| 33 |
NCT01986270 |
Completed |
Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo |
- Migraine With or Without Aura
|
- Drug: Placebo
- Drug: Eletriptan 40 mg
- Drug: Eletriptan 80 mg
- (and 2 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Headache response at 1 hour after the first dose for the first attack.
- Pain-free response at 1 hour after the first dose for the first attack.
|
1141 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01986270 |
A160-104 |
|
December 1996 |
January 1998 |
January 1998 |
November 18, 2013 |
November 18, 2013 |
|
|
|
| 34 |
NCT01986088 |
Completed |
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study |
- Migraine With or Without Aura
|
- Drug: Placebo
- Drug: Eletriptan 40 mg
- Drug: Eletriptan 80 mg
- (and 2 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Headache response at 1 hour after treatment of the first attack.
- Headache severity
- Pain-free response
- (and 2 more...)
|
1008 |
All |
18 Years to 76 Years (Adult, Older Adult) |
NCT01986088 |
A160-318 |
|
November 1996 |
January 1998 |
January 1998 |
November 18, 2013 |
November 18, 2013 |
|
|
|
| 35 |
NCT01978496 |
Completed |
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine |
- Migraine With or Without Aura
|
- Drug: Placebo
- Drug: Eletriptan 20 mg
- Drug: Eletriptan 40 mg
- Drug: Eletriptan 80 mg
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Headache responder rate at two hours after the first dose for the first attack.
- Pain free responder rate at two hours after the first dose for the first attack.
|
1334 |
All |
18 Years to 78 Years (Adult, Older Adult) |
NCT01978496 |
A160-102 |
|
July 1996 |
December 1997 |
December 1997 |
November 7, 2013 |
November 13, 2013 |
|
|
|
| 36 |
NCT00334178 |
Completed |
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine |
- Migraine With Aura
- Migraine Without Aura
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- change from baseline in the frequency of migraine attacks
- change from baseline in 4-week in migraine periods of week 9 to 12;
- change from baseline in 4-week in migraine days of week 9 to 12;
- (and 4 more...)
|
74 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00334178 |
LAXY-P001-R-2003 |
|
November 2004 |
|
September 2006 |
June 6, 2006 |
September 10, 2007 |
|
- Changhua Christian Hospital
Changhua, Taiwan - Chung-Ho Memorial Hospital, Kaohsiung Medical University
Kaohsiung, Taiwan - Chang-Gung Memorial Hospital
LinKou, Taiwan - (and 4 more...)
|
|
| 37 |
NCT03301441 |
Recruiting |
Sensitivity to Acute Cerebral Ischemia in Migrainers |
- Ischemic Stroke
- Migraine
- Migraine With Aura
|
- Other: questionnaire ef-ID Migraine
|
Observational
|
|
- University Hospital, Montpellier
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mismatch ratio (MRI DWI/PWI or CT rCBF/CTP)
- Proportion of patients with no-mismatch pattern on initial imaging
- Proportion of patients treated by recanalisation
- (and 4 more...)
|
600 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03301441 |
9789 |
SAMCO-MIG |
February 9, 2018 |
February 2021 |
February 2021 |
October 4, 2017 |
March 29, 2018 |
|
- CHU de Montpellier - Neurology Departement
Montpellier, France
|
|
| 38 |
NCT00471952 |
Completed |
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache |
- Migraine With Aura
- Migraine Without Aura
|
- Drug: Maxalt 10mg MLT plus Caffeine 75mg
- Drug: Maxalt 10mg MLT plus Placebo
- Drug: Placebo + Placebo
|
Interventional
|
Phase 3 |
- Diamond Headache Clinic
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- The comparative percentage of migraine attacks that produce pain free response at 2 hours in the Maxalt 10mg MLT plus caffeine 75mg arm versus the Maxalt 10mg MLT plus placebo caffeine versus double placebo.
- The comparative percentage of attacks that produce pain relief at 2 hours.
- The comparative percentage of attacks that produce a pain free response and do not require re-treatment during the subsequent 24 hours and are not associated with headache pain recurrence.
- (and 3 more...)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00471952 |
DHC 09 |
|
April 2007 |
February 2008 |
April 2008 |
May 10, 2007 |
April 25, 2012 |
|
- Diamond Headache Clinic
Chicago, Illinois, United States
|
|
| 39 |
NCT03217968 |
Completed
Has Results |
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device |
|
- Device: Cefaly® Abortive Program device
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain Freedom (PF) at 2 Hours
- Most Bothersome Migraine-associated Symptom (MBS) Freedom at 2 Hours
- Pain Relief (PR) at 2 Hours
- (and 3 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03217968 |
50803 |
|
August 10, 2017 |
January 10, 2018 |
January 10, 2018 |
July 14, 2017 |
June 7, 2018 |
June 7, 2018 |
- Rochester Clinical Research, Inc.
Rochester, New York, United States
|
|
| 40 |
NCT00123201 |
Completed |
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache |
- Migraine With Aura
- Migraine Without Aura
|
|
Interventional
|
Phase 2 |
- Solvay Pharmaceuticals
- Nektar Therapeutics
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00123201 |
S175.2.103 |
|
September 2005 |
March 2007 |
March 2007 |
July 22, 2005 |
January 16, 2015 |
|
- Site 10
Huntsville, Alabama, United States - Site 8
Huntsville, Alabama, United States - Site 11
Tucson, Arizona, United States - (and 26 more...)
|
|
| 41 |
NCT02590939 |
Completed
Has Results |
Acute Treatment of Migraine With e-TNS |
|
- Device: CEFALY Active
- Device: CEFALY Placebo
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Pain Score 1-hour
- Rescue Medication 2 Hours
- Pain Score 2 Hours
- (and 2 more...)
|
106 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02590939 |
50213 |
ACME |
February 1, 2016 |
March 31, 2017 |
March 31, 2017 |
October 29, 2015 |
June 6, 2018 |
April 9, 2018 |
- Yale University School of Medicine
New Haven, Connecticut, United States - Rowe Neurology Institute
Lenexa, Kansas, United States - Columbia University Medical Center
New York, New York, United States
|
|
| 42 |
NCT00534560 |
Completed |
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache |
- Migraine Without Aura
- Migraine With Aura
|
- Drug: Tonabersat
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Reduction in the mean monthly number of migraine attacks over the last 2 months of the treatment period.
- Safety and tolerability: incidence of all AEs, serious adverse events (SAEs) and those leading to withdrawal of study medication, review of laboratory data, including hematology, biochemistry, and urinalysis, physical examinations, and vital signs.
- Assessment of population pharmacokinetics for tonabersat - blood samples will be collected from a sub-population of patients
- (and 8 more...)
|
542 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00534560 |
TON/03/07-CLIN |
TEMPUS |
October 2007 |
November 2008 |
March 2009 |
September 26, 2007 |
March 31, 2009 |
|
|
|
| 43 |
NCT00311662 |
Completed |
Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache |
- Migraine Without Aura
- Migraine With Aura
|
- Drug: Tonabersat
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in the mean monthly number of migraine headache days from the baseline period to Month 3.
- Incidence of all adverse events (AEs), serious AEs and AEs leading to withdrawal of trial medication, clinical laboratory tests, vital signs and physical examination
- Change in the mean monthly number of migraine headache days from the baseline period to across the whole treatment period.
- (and 9 more...)
|
124 |
All |
18 Years to 55 Years (Adult) |
NCT00311662 |
TON/01/05-CLIN |
|
April 2006 |
October 2006 |
October 2006 |
April 6, 2006 |
August 31, 2009 |
|
- Glostrup Amtssygehus, Neurologisk Ambulatorium N01
Copenhagen, Denmark - Bispebjerg Hospital, Neurolgisk Afdeling N
Copenhagen, Denmark - Kenézy Gyula County Hospital, Dept of Neurology
Debrecen, Hungary - (and 14 more...)
|
|
| 44 |
NCT02342743 |
Completed |
Open-trial on the Prevention of Chronic Migraines With the CEFALY Device |
|
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change from baseline in frequency of headache days
- Change from baseline in acute medication intake
- Change in frequency of migraine days
- (and 5 more...)
|
73 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02342743 |
50207 |
|
February 2, 2015 |
April 11, 2017 |
April 11, 2017 |
January 21, 2015 |
May 1, 2017 |
|
- University of Colorado Anschutz Medical Campus - Department of Neurology
Aurora, Colorado, United States
|
|
| 45 |
NCT03536936 |
Completed
New |
Oxygenation and Perfusion in Patients With Acute Migraine Attacks |
- Migraine
- Migraine With Aura
- Migraine; Status
|
|
Observational
|
|
- University Hospital Inselspital, Berne
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Focal cerebral hypoperfusion and elevated oxygenation in acute migraine attack
|
1000 |
All |
6 Years to 80 Years (Child, Adult, Older Adult) |
NCT03536936 |
Migraine Brain Perfusion |
OPAMA |
January 1, 2010 |
April 30, 2018 |
April 30, 2018 |
May 25, 2018 |
May 25, 2018 |
|
|
|
| 46 |
NCT00599586 |
Completed |
Randomized Controlled Trial of Treating Migraine With Acupuncture |
|
|
Interventional
|
Not Applicable |
- Chengdu University of Traditional Chinese Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- number of days with migraine
- frequency of migraine attacks
- Migraine-Specific Quality-of-Life Questionnaire
- Transcranial Doppler Sonography
|
480 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00599586 |
2006CB5045011 |
|
November 2007 |
September 2009 |
September 2009 |
January 24, 2008 |
June 29, 2010 |
|
- Chengdu University of TCM
Chengdu, Sichuan, China
|
|
| 47 |
NCT01667679 |
Completed
Has Results |
Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura |
|
- Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
- Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Sum of Migraine Pain Intensity Differences (SPID)-30
- Mean Sum of Migraine Pain Intensity Differences (SPID)-30 for Headaches With a Baseline Intensity of Mild and Moderate/Severe
- Percentage of Attacks in Which Pain Reduction Was Achieved
- (and 24 more...)
|
275 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01667679 |
OPN-SUM-MIG-3302 |
COMPASS |
August 2012 |
March 2014 |
June 2014 |
August 17, 2012 |
April 12, 2017 |
March 14, 2017 |
- San Francisco Clinical Research Center
San Francisco, California, United States - California Medical Clinic for Headache
Santa Monica, California, United States - Associated Neurologists of Southern CT, P.C.
Fairfied, Connecticut, United States - (and 10 more...)
|
|
| 48 |
NCT00442936 |
Completed
Has Results |
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011) |
|
- Drug: Telcagepant potassium 150 mg
- Drug: Telcagepant potassium 300 mg
- Drug: Zolmitriptan 5 mg
- (and 4 more...)
|
Interventional
|
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose
- Number of Participants With Pain Relief (PR) at 2 Hours Post-Dose
- Number of Participants With Absence of Photophobia at 2 Hours Post-Dose
- (and 7 more...)
|
1380 |
All |
18 Years and older (Adult, Older Adult) |
NCT00442936 |
0974-011
MK-0974-011
2006_525 |
|
February 15, 2007 |
October 2, 2007 |
October 2, 2007 |
March 5, 2007 |
May 12, 2017 |
August 4, 2014 |
|
|
| 49 |
NCT00758836 |
Completed
Has Results |
A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046) |
|
- Drug: placebo
- Drug: ibuprofen
- Drug: acetominophen
- Drug: telcagepant
|
Interventional
|
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants With Pain Freedom at Two Hours Post-dose
- Number of Participants Experiencing Adverse Events Within 48 Hours Post-dose (Count ≥4 in One or More Treatment Groups)
- Number of Participants Experiencing Adverse Events Within 14 Days Post-dose (Count ≥4 in One or More Treatment Groups)
- Percentage of Participants With Pain Relief at 2 Hours Post-dose.
|
683 |
All |
18 Years and older (Adult, Older Adult) |
NCT00758836 |
0974-046
2008_551
CTRI/2009/091/000291 |
|
December 3, 2008 |
August 24, 2009 |
August 24, 2009 |
September 25, 2008 |
June 20, 2017 |
August 11, 2014 |
|
|
| 50 |
NCT03479060 |
Completed |
Continue or Stop Applying Wet Cupping (Al-Hijamah) in Migraine |
- Migraine Disorders
- Migraine With Aura
- Migraine Without Aura
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
109 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03479060 |
KBU-BAP-14/1-KA-057. |
|
January 3, 2017 |
February 1, 2018 |
March 1, 2018 |
March 27, 2018 |
June 6, 2018 |
|
- Karabuk University Karabuk Research and Education hospital
Karabük, Karabuk, Turkey
|
|
Create an RSS feed from your search for:
Download the search results for: